The Metered Dose Inhaler (MDI) manufacturing plant of Beximco Pharma is one of the finest facilities in the world to produce Ozone benign HFA based MDI products. The plant was designed and installed under the technical collaboration of Pamasol, Switzerland.

The facility has dedicated areas for dispensing, manufacturing, canister and valve cleaning, canister filling, quarantine storage area, spray testing, packaging, propellant storage and in process control. As the inhaler manufacturing operation requires stringent control of humidity and temperature, automatic monitoring equipment are in use to continuously record temperature and relative humidity in areas like dispensing room, suspension manufacturing room, filling room, quarantine room etc.

The manufacturing equipment like manufacturing vessel, filling machine, weight checker, spray checking have been procured from Pamasol, Switzerland, a world renowned equipment supplier for Inhaler product manufacturing. The state-of-the-art Quality Control laboratory has been equipped with equipment like HPLC, Karl Fischer Titrator, Andersen Cascade Impactor etc.

Our MDI facility is the only approved outsourced facility of GlaxoSmithKline for their Ventolin^® inhaler. We are happy to make our production and technical facilities open to inspection by existing and potential customers.

Our MDI plant has been audited by many local and overseas auditors and was acclaimed by them.

Due to the potential risk to the environment posed by CFCs, the technology shift in MDI industry is currently towards using hydrofluoroalkane (HFA) as propellants. Considering this changing trend in pulmonary drug delivery technologies, the company has aready developed the HFA based MDIs which inevitably requires very high level of expertise and sophisticated technology. We are among the very few companies in the world manufactuing CFC-free HFA MDIs.

Now with this state-of-the-art MDI facility, the company aims at obtaining marketing approvals from stringent regulatory authorities of the developed markets.